Kalos Founder Speaks at Bio Tech Showcase 2012

Jan. 7, 2012 - PRLog -- Kalos Therapeutics announced George Colberg, Executive Chairman will be presenting at the Biotech Showcase 2012 in San Francisco hosted by The EBD group in collaboration with Demy-Colton Life Science Advisors, and the showcases introduce new companies developing breakthrough technologies.  The meeting will coincide with the festivities of the JP Morgan gathering making this the Super bowl of Pharma and Biomedical financing and introducing scientific breakthroughs for these participants.

George Colberg, Executive Chairman of Kalos, said, "We are very encouraged by our research results, particularly in light of new applications for our ANP peptide product in AMD. This new approach may allow for delivery via eye drop and in a preventative care setting.” Changing the entire market for treating age related blindness, without intravitreal injections. The Company will be introducing a recently discovered application of its therapy in Adult Macular Degeneration, (AMD) which may provide a therapeutic and prophylactic application in this eye disease.

The Company continues to move its core products forward  in virulent cancers like pancreatic and ovarian, in a unique manner eliminating chemo-related side effect while leveraging the natural effects of ANP peptides in the body, whereby producing a cytostatic approach to treating these cancers, while reducing pain and edema related to abdominal cancers.

About Kalos Therapeutics:  Kalos Therapeutics is a biopharmaceutical company that develops and commercializes proprietary product candidates primarily for the treatment of cancer and age related diseases. The ANP family of peptides represents a portfolio from which many therapeutics can be developed addressing multiple indications within cancer, age related diseases and non-malignant hyperproliferative disorders.

Kalos is a uniquely positioned biomedical company whose family of peptide therapeutics has previous successful clinical experience in humans.  Kalos is pioneering an approach to treat cancer by developing peptides made primarily in the heart, as a cytostatic therapeutic for treating aggressive cancers by engaging known pathway receptors more efficiently without the side effects associated with chemotherapeutic or small molecule compounds.

More information can be found on Kalos' web site at http://www.kalostherapeutics.com

Contact:
Kalos Therapeutics George Colberg, Executive Chairman 858-385-1290 or gcolberg@kalostpx.com

info@kalostpx.com

SOURCE:  Kalos Therapeutics, North America, California

INDUSTRY KEYWORDS: Biotechnology, Clinical Trials, Oncology, AMD, Pharmaceutical, Research, Health,

# # #

Kalos Therapeutics, Inc. is targeting diseases causedby an abnormally high growth rate of cells (hyperproliferation). Our strategy is to harness the natural antiproliferative activity of the (ANP)family of peptides controling cancer and AMD